Can a simple scan predict lung cancer treatment success?
NCT ID NCT03832348
First seen Jan 06, 2026 · Last updated Jun 22, 2026 · Updated 18 times
Summary
This study looked at 40 people with advanced non-small cell lung cancer who were starting treatment with the drug pembrolizumab. Researchers used special PET scans after each of the first three doses to see how the cancer's metabolism changed. The goal was to find out if early scan results could predict whether the treatment would work after three months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHU
Rouen, 76000, France
-
Centre Henri Becquerel
Rouen, 76000, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab
What this could lead to
If successful, this could help doctors use early PET scans to quickly tell if pembrolizumab is working for lung cancer patients.
What could go wrong
This is a small, completed observational study with only 40 participants. It does not test a new treatment, so it may not change how doctors treat lung cancer.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.